Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$80 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-3.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.2
Industry P/E
--
EV/EBITDA
-0.4
Div. Yield
0 %
Debt to Equity
0.3
Book Value
$0.7
EPS
$-2.1
Face value
--
Shares outstanding
19,083,236
CFO
$-168.19 Mln
EBITDA
$-231.50 Mln
Net Profit
$-202.86 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PolyPid (PYPD)
| 1.2 | 3.3 | 1.2 | 59.7 | -31.7 | -56.7 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
PolyPid (PYPD)
| 42.8 | -81.8 | -87.8 | -42.0 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PolyPid (PYPD)
|
4.4 | 80.3 | 0.0 | -34.2 | -- | -366.3 | -- | 7.2 |
| 8.5 | 466.6 | 195.3 | 21.9 | 12.7 | 8.3 | 23.1 | 1.8 | |
| 16.8 | 198.6 | 17.0 | -23.9 | -96.8 | -63.9 | -- | 4.5 | |
| 2.1 | 1.9 | 0.0 | -4.8 | -- | -93.3 | 0 | 0.2 |
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product... candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. Address: 18 Hasivim Street, Petah Tikva, Israel, 4959376 Read more
CEO & Director
Ms. Dikla Czaczkes Akselbrad
CEO & Director
Ms. Dikla Czaczkes Akselbrad
Headquarters
Petah Tikva
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of PolyPid (PYPD) is $4.39 (NASDAQ) as of 02-Apr-2026 16:00 EDT. PolyPid (PYPD) has given a return of -31.74% in the last 3 years.
Since, TTM earnings of PolyPid (PYPD) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-2.03
|
6.33
|
|
2024
|
-0.63
|
2.37
|
|
2023
|
-0.16
|
-1.81
|
|
2022
|
-0.02
|
0.12
|
|
2021
|
-0.14
|
0.16
|
The 52-week high and low of PolyPid (PYPD) are Rs 5.12 and Rs 2.30 as of 04-Apr-2026.
PolyPid (PYPD) has a market capitalisation of $ 80 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in PolyPid (PYPD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.